BREAKING
Importance
55
Trust
76
Urgency
95
DEAL✓ 3 outlets
Hytn announces proposed spin-out of BPC-157 peptide drug development business - marketscreener.com
Hytn plans to separate its BPC-157 drug development business into its own company. BPC-157 is a peptide being studied as a potential treatment for various conditions.
Analysis
BPC-157 is mostly sold today through gray-market peptide shops. A real drug developer working on it could push the peptide toward formal clinical testing.
- Hytn plans to spin out its BPC-157 drug development business into a separate company
- BPC-157 is a peptide being studied for various conditions
Peptide Therapy Research1mo
Read